LFM-A13
SIGMA/L6920 - ≥98% (HPLC), powder
Synonym: α-Cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide; (2Z)
CAS Number: 244240-24-2
Empirical Formula (Hill Notation): C11H8Br2N2O2
Molecular Weight: 360.00
MDL Number: MFCD09878279
Linear Formula: C11H8Br2N2O2
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to tan |
| form | powder |
| InChI | 1S/C11H8Br2N2O2/c1-6(16)8 |
| InChI key | UVSVTDVJQAJIFG-VURMDHGXSA |
| Quality Level | 100 ![]() |
| SMILES string | CC(O)=C(/C#N)C(=O)Nc1cc( |
| solubility | DMSO: ≥19 mg/mL |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | LFM-A13 is a potent and selective inhibitor of Bruton′s tyrosine kinase (BTK) |
| Biochem/physiol Actions: | LFM-A13 is an inhibitor of the nonreceptor tyrosine kinase Bruton′s tyrosine kinase (Btk), a new molecular target for treatment of B-cell lymphoma and autoimmune disorders. LFMA13 inhibited recombinant BTK with an IC50 value of 2.5microM with 100-fold lower inhibitory activity against a number of other protein kinases including JAK1, JAK2, EGFR, IRK, IKK, and CDK1, 2 and 3, as well as several other related kinases |
| Features and Benefits: | This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm . |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 + H312 + H332 |
| Precautionary statements | P280 - P301 + P312 + P330 - P302 + P352 + P312 - P304 + P340 + P312 |
| Hazard Codes | Xn |
| Risk Statements | 20/21/22 |
| Safety Statements | 36/37 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |


